What new insights did the LOTUS study reveal about DAYBUE’s long-term real-world impact on Rett syndrome patients?
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) has published interim results from its ongoing LOTUS study, confirming that DAYBUE® (trofinetide) continues to deliver meaningful symptom improvements for patients with Rett syndrome up to 12 months after treatment initiation. The findings were released in the peer-reviewed journal Developmental Medicine and Child Neurology and reflect caregiver-reported outcomes gathered under real-world clinical use conditions in the United States.
The LOTUS study, which involves 227 patients aged 1 to 60 years old, builds on the foundation of the Phase 3 LAVENDER™ trial and its associated open-label extensions—LILAC, LILAC-2, and DAFFODIL. These earlier studies supported DAYBUE’s U.S. FDA approval in March 2023 as the first and only therapy for Rett syndrome. According to Acadia Pharmaceuticals, the new data reinforce DAYBUE’s tolerability and sustained behavioral benefits in daily care settings.
How do the LOTUS outcomes compare with prior clinical trials like LAVENDER and LILAC?
While randomized clinical trials such as LAVENDER established the drug’s efficacy in controlled environments, the LOTUS study offers a valuable real-world perspective. Caregivers reported that between 71% and 90% of patients showed improvements in at least one behavioral domain, as measured by Acadia’s custom-developed Behavioral Improvement Questionnaire (BIQ).
Reported gains most frequently included better nonverbal communication (48%–71%), increased alertness (44%–70%), and stronger social interaction and connectedness (33%–58%). These results closely mirror patterns seen in prior clinical trials and suggest that benefits are durable beyond the initial 12-week clinical windows.
Quality-of-life metrics also showed encouraging movement. Patients with both baseline and 12-month assessments (n=33) recorded a median QI-Disability score improvement of +4.6 points—another indication of sustained progress in daily functioning.
What does the study reveal about tolerability, side effects, and dosage adjustments over time?
Despite the long-term treatment duration, DAYBUE’s safety profile remained consistent with expectations. The most common adverse event was diarrhea, which affected 23% to 50% of participants in weeks 1–12 and 26% to 38% in months 4–12. Caregivers reported that most episodes were contained in diapers and were managed with standard interventions such as discontinuing constipation medication, increasing fluids and dietary fiber, or using over-the-counter antidiarrheals.
Over time, stool patterns improved, with 43%–54% of participants reporting normal stools in early weeks and up to 63% in later months. Vomiting, another known side effect, was reported in fewer than one-third of participants.
Interestingly, median dosing started at about 36% of the FDA’s target weight-banded dose and increased to over 80% by week 10. This slow titration pattern suggests caregivers and clinicians are adopting a cautious, personalized dosing approach to balance efficacy with tolerability in real-world use.
How reliable are the LOTUS study results given its observational design and caregiver-led assessments?
While the LOTUS study provides rich longitudinal data, several limitations require caution in interpretation. The study lacks a placebo-controlled arm and is reliant entirely on caregiver-reported outcomes rather than clinician-validated scales. Both the BIQ and Gastrointestinal Health Questionnaire, developed by Acadia for this study, are not yet externally validated.
Moreover, since the study is ongoing and participant drop-off increases at later timepoints, the 12-month dataset is not yet comprehensive. Still, the consistency of symptom improvement across multiple domains and age groups strengthens confidence in the broader therapeutic value of DAYBUE.
Acadia has acknowledged these caveats while highlighting the practical value of real-world data, especially in rare diseases where clinical trial enrollment is often limited and diverse presentations of disease progression can be hard to capture in short-term studies.
What does the new data mean for investor sentiment and Acadia’s long-term strategy in neuro-rare diseases?
Institutional response to the LOTUS results has been cautiously optimistic. Analysts covering the neuro-rare disease space point out that sustained real-world efficacy could help support stronger insurance coverage, longer treatment durations, and expanded physician confidence. This could prove critical for DAYBUE’s revenue trajectory in 2026 and beyond.
Acadia Pharmaceuticals, which also markets pimavanserin for Parkinson’s disease psychosis, has been positioning DAYBUE as a long-term anchor in its pipeline. With over 6,000 to 9,000 patients in the U.S. eligible for treatment, even modest real-world retention could translate into a meaningful revenue stream.
The firm is also expanding its development programs across multiple neuro-rare indications, including Prader-Willi syndrome and Alzheimer’s-related psychosis. Success with DAYBUE could serve as a proof point in building institutional trust across these parallel efforts.
How does DAYBUE work, and why is it significant for the Rett syndrome community?
DAYBUE (trofinetide) is a synthetic analog of the N-terminal tripeptide of IGF-1. While its exact mechanism remains unclear, preclinical data suggest it may support synaptic connectivity and dendritic branching—areas disrupted in Rett syndrome due to mutations in the MECP2 gene.
The condition, which affects approximately 1 in every 10,000 to 15,000 female births worldwide, is characterized by early developmental regression, motor deterioration, hand stereotypies, and severe communication impairments. With no disease-modifying options historically available, DAYBUE’s approval marked a pivotal moment for patients, caregivers, and advocacy groups.
Most Rett patients live into adulthood and require continuous care. The fact that the LOTUS study included adult participants and showed symptom improvements in this subset adds further weight to the therapy’s broader applicability and emotional significance for long-underserved patient populations.
What are the safety warnings associated with DAYBUE, and what monitoring is required during treatment?
As noted in the prescribing information, diarrhea affects over 80% of patients and should be monitored closely. Other reported issues include vomiting (29%), weight loss greater than 7% from baseline (12% of patients), and occasional fatigue, seizures, and decreased appetite.
DAYBUE is not recommended for patients with severe renal impairment. It is an oral solution (200 mg/mL) and may interact with CYP3A and P-gp substrates, requiring careful drug monitoring. Physicians are advised to discontinue laxatives before initiating therapy and to intervene promptly if dehydration or weight loss is detected.
What is the next milestone for DAYBUE and the LOTUS study in 2025–2026?
Looking ahead, Acadia plans to continue enrolling patients in the LOTUS study for at least another 12 months, with the option for participants to extend follow-up for an additional year. Upcoming data readouts are expected to include a larger cohort at the 18- and 24-month marks.
Analysts also expect more refined dosing guidance, efforts to validate custom caregiver-reported instruments, and perhaps expanded geographic data collection beyond the U.S. With continued durability in symptom relief and manageable safety outcomes, DAYBUE’s position as a foundational treatment for Rett syndrome is likely to grow.
Discover more from Business-News-Today.com
Subscribe to get the latest posts sent to your email.
